| 2.4 -0.06 (-2.44%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.3  |
1-year : | 3.62 |
| Resists | First : | 2.83 |
Second : | 3.09 |
| Pivot price | 2.63 |
|||
| Supports | First : | 2.4 |
Second : | 1.99 |
| MAs | MA(5) : | 2.49 |
MA(20) : | 2.68 |
| MA(100) : | 2.86 |
MA(250) : | 3.3 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.1 |
D(3) : | 9.9 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 5.46 | Low : | 2.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ANIX ] has closed above bottom band by 0.2%. Bollinger Bands are 14% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.52 - 2.54 | 2.54 - 2.56 |
| Low: | 2.36 - 2.38 | 2.38 - 2.4 |
| Close: | 2.37 - 2.41 | 2.41 - 2.43 |
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Mon, 01 Jun 2026
Ovarian cancer vaccine targeting 'retired' protein wins Canada patent backing - Stock Titan
Mon, 11 May 2026
/C O R R E C T I O N -- Anixa Biosciences, Inc./ - PR Newswire
Fri, 01 May 2026
Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data - Stock Titan
Wed, 29 Apr 2026
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 15.4 (%) |
| Shares Short | 983 (K) |
| Shares Short P.Month | 1,040 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.4 % |
| Return on Equity (ttm) | -68.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -7.51 |
| PEG Ratio | -0.2 |
| Price to Book value | 5.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|